<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30145739</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>26</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1433-7339</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>25</Day>                    </PubDate>                </JournalIssue>                <Title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</Title>                <ISOAbbreviation>Support Care Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>What determines the timing of discussions on forgoing anticancer treatment? A national survey of medical oncologists.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00520-018-4423-7</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">End-of-life discussions (EOLd) including the option of forgoing anticancer treatment infrequently occur until treatment options have been exhausted for advanced cancer patients. We aimed to identify oncologist-related factors contributing to the timing of discussing the option of forgoing anticancer treatment.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">In this nationwide survey of 864 medical oncologists, we asked about physicians' attitudes toward the timing of discussing the option of forgoing anticancer treatment for a simulated patient with newly diagnosed metastatic cancer, physicians' experience of EOLd, perceptions of a good death, and beliefs. Multivariate analyses identified determinants of early discussions.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 490 physicians (response rate = 57%), 167 (35%) would discuss the option of forgoing anticancer treatment &quot;now (at the diagnosis).&quot; Physicians' attitudes toward discussing the option &quot;now&quot; were significantly correlated with a greater physician-perceived importance of life completion (odds ratio (OR) = 1.30, 95%CI = 1.00-1.69, p = 0.048) and dying in a preferred place (OR = 1.29, 95%CI = 1.01-1.65, p = 0.045) for a good death, and not perceiving EOLd as being severely distressing for patients/families (OR = 0.70, 95%CI = 0.54-0.95, p = 0.021). In multivariate analyses, independent determinants of the attitude toward discussing the option now included a greater physician-perceived importance of life completion for a good death (OR = 1.38, 95%CI = 1.05-1.81, p = 0.019), and not perceiving EOLd as being severely distressing for patients/families (OR = 0.70, 95%CI = 0.52-0.94, p = 0.017).</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Reflection by oncologists on their own perception regarding a good death and beliefs about EOLd may help oncologists individualize the timing of discussing the option of forgoing anticancer treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mori</LastName>                    <ForeName>Masanori</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Palliative Care Team, Seirei Mikatahara General Hospital, 3453 Mikataharacho, Kita-ku, Hamamatsu, Shizuoka, 433-8558, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shimizu</LastName>                    <ForeName>Chikako</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku, Tokyo, 162-8655, Japan. cshimizu@hosp.ncgm.go.jp.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ogawa</LastName>                    <ForeName>Asao</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Psycho-Oncology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Okusaka</LastName>                    <ForeName>Takuji</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yoshida</LastName>                    <ForeName>Saran</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Graduate School of Education, Tohoku University, 27-1, Kawauchi, Aoba-ku, Sendai, Miyagi, 980-8576, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morita</LastName>                    <ForeName>Tatsuya</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Palliative and Supportive Care Division, Seirei Mikatahara General Hospital, 3453 Mikataharacho, Kita-ku, Hamamatsu, Shizuoka, 433-8558, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>25-B-5</GrantID>                    <Agency>National Cancer Center Research and Development Fund</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>JP16K15418</GrantID>                    <Agency>Japan Society for the Promotion of Science KAKENHI</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Support Care Cancer</MedlineTA>            <NlmUniqueID>9302957</NlmUniqueID>            <ISSNLinking>0941-4355</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Attitude</Keyword>            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Communication</Keyword>            <Keyword MajorTopicYN="N">Oncologists</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30145739</ArticleId>            <ArticleId IdType="doi">10.1007/s00520-018-4423-7</ArticleId>            <ArticleId IdType="pii">10.1007/s00520-018-4423-7</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>